随着冠状病毒在世界范围内迅速传播，目前新冠肺炎确诊病例已近80万。由此国内外已有60余家科研机构和疫苗企业参与新冠疫苗的研发。新型疫苗研发，如何评价其有效性至关重要。近日我国科学家在EMI杂志在线发表了题为“Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2”的研究论文。该研究可作为替代方法在生物安全二级实验室进行病毒中和试验，以此来评价疫苗的有效性，这将加速新冠疫苗研发进程，具有重要的理论和实际应用意义。
附文献信息：PDF全文可通过点击文末的阅读原文获得
DOI：10.1080/22221751.2020.1743767
Abstract：Pseudoviruses are useful virological tools because of their safety and versatility, especially for emerging and re-emerging viruses. Due to its high pathogenicity and infectivity and the lack of effective vaccines and therapeutics, live SARS-CoV-2 has to be handled under biosafety level 3 conditions, which has hindered the development of vaccines and therapeutics. Based on a VSV pseudovirus production system, a pseudovirus-based neutralization assay has been developed for evaluating neutralizing antibodies against SARS-CoV-2 in biosafety level 2 facilities. The key parameters for this assay were optimized, including cell types, cell numbers, virus inoculum. When tested against the SARS-CoV-2 pseudovirus, SARS-CoV-2 convalescent patient sera showed high neutralizing potency, which underscore its potential as therapeutics. The limit of detection for this assay was determined as 22.1 and 43.2 for human and mouse serum samples respectively using a panel of 120 negative samples. The cutoff values were set as 30 and 50 for human and mouse serum samples, respectively. This assay showed relatively low coefficient of variations with 15.9% and 16.2% for the intra- and inter-assay analyses respectively. Taken together, we established a robust pseudovirus-based neutralization assay for SARS-CoV-2 and are glad to share pseudoviruses and related protocols with the developers of vaccines or therapeutics to fight against this lethal virus.作者: ms003 时间: 2020-4-4 07:49
PDF文献全文：